Changes of Macrophage Migration Inhibitory Factor During Orthotopic Liver Transplantation

Changes of Macrophage Migration Inhibitory Factor and Thyroid Hormones During Liver Transplantation. Association With Graft Dysfunction

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02695979

Enrollment

100

Registered

2016-03-02

Start date

2014-08-31

Completion date

2019-08-31

Last updated

2018-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evidence of Liver Transplantation

Brief summary

Collecting blood, graft liver effluent and urine samples from patients undergoing orthotopic liver transplantation.

Detailed description

Aims are to measure Macrophage Migration Inhibitory Factor, Macrophage Migration Inhibitory Factor II and its' soluble receptor CD74 in serum, liver graft effluent and urine in and evaluate MIF's role in hepatic ischemia/reperfusion injury, postoperative graft function and kidney function.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* End stage liver disease, chronic liver failure, orthotopic liver transplantation

Exclusion criteria

* Combined transplantations (liver plus kidney or lung), age under 18 y, acute liver failure

Design outcomes

Primary

Measure	Time frame
Macrophage Migration Inhibitory Factor in human serum, liver graft effluent and urine	24 months

Other

Measure	Time frame	Description
Acute kidney injury, outcome	48 months	Acute kidney injury, outcome

Countries

Austria

Outcome results